6533b839fe1ef96bd12a5704
RESEARCH PRODUCT
Capturing colorectal cancer inter-tumor heterogeneity in patient-derived xenograft (PDX) models
Pramudita R. PrasetyantiSander R. Van HooffTessa Van HerwaardenNathalie De VriesKieshen KalloeHans RodermondRonald Van LeersumJoan H. De JongMarek FranitzaPeter NürnbergMatilde TodaroGiorgio StassiJan Paul Medemasubject
Tumor Markers and SignaturesCMSShort Reportcolorectal cancerXenograft Model Antitumor AssaysDisease Models AnimalMicecell proliferationxenograft CMStumor subtypeAnimalsHeterograftsHumansxenograftColorectal NeoplasmsPDXdescription
Patient‐derived xenograft (PDX) models have become an important asset in translational cancer research. However, to provide a robust preclinical platform, PDXs need to accommodate the tumor heterogeneity that is observed in patients. Colorectal cancer (CRC) can be stratified into four consensus molecular subtypes (CMS) with distinct biological and clinical features. Surprisingly, using a set of CRC patients, we revealed the partial representation of tumor heterogeneity in PDX models. The epithelial subtypes, the largest subgroups of CRC subtype, were very ineffective in establishing PDXs, indicating the need for further optimization to develop an effective personalized therapeutic approach to CRC. Moreover, we showed that tumor cell proliferation was associated with successful PDX establishment and able to distinguish patient with poor clinical outcomes within CMS2 group.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2019-01-01 |